冯雪苹,宋鑫

• 1:昆明医学院第三附属医院
• 2:云南省肿瘤医院生物治疗中心

摘要(Abstract)：

<正>肺癌是目前世界上癌症死亡的主要原因[1],其中非小细胞肺癌(non-small cell lung cancer,NSCLC)占肺癌的80%～85%[2],大多数非小细胞肺癌患者确诊时已属ⅢB或Ⅳ期,尽管以铂类为基础的联合化疗使晚期NSCLC患者生存得到很大程

关键词(KeyWords)： 癌,非小细胞肺;分子生物学;受体,表皮生长因子;酪氨酸激酶抑制剂;抗药性;治疗结果;药物疗法;预后

Abstract:

Keywords:

基金项目(Foundation): 国家高科技研究发展计划(863)(2012AA02A201);; 国家“十二·五”计划国家科技重大专项(2011ZX09102);; 国家自然科学基金(81060185,30671904,30760014);; 国家教育部新世纪优秀人才支持计划项目(NCET-08-0923);; 云南省科技计划项目-科技创新强省计划国际科技合作专项(2009AC016);; 云南省应用基础研究面上项目(2011FB209);; 云南省应用基础研究重点项目(2008CC006);; 云南省卫生科技计划项目(2010NS081,2009NS017);; 云南省卫生厅科技内设研究机构项目(2011WS0075);; 云南省教育厅科学研究基金项目(2011J043);; 昆明市科技计划重点项目(07S060202);; 昆明医学院研究生创新基金项目(2011N07);; 云南省引进高层次人才政府工作经费资助(60100122);; 高层次人才培引工程;; 云南省肿瘤医院肺癌防治省创新人才团队(20080C014);; 云南省一类省级肿瘤学重点学科建设项目基金;; 昆明医学院优先扶持肿瘤学重点学科建设项目基金

作者(Author): 冯雪苹,宋鑫

DOI: 10.13267/j.cnki.syzlzz.2012.05.029

参考文献(References)：

• [1]Custodio A,Méndez M,Provencio M.Targeted therapiesfor advanced non-small cell lung cancer:current statusand future implications[J].Cancer Treat Rev,2012,38(1):36-53.
• [2]Dacic S.Molecular diagnostics of lung carcinomas[J].Arch Pathol Lab Med,2011,135(5):622-629.
• [3]Pallis AG,Fennell DA,Szutowicz E,et al.Biomarkers ofclinical benefit for anti-epidermal growth factor receptoragents in patients with non-small cell lung cancer[J].BrJ Cancer,2011,105(1):1-8.
• [4]Van Dyke AL,Cote ML,Prysak GM,et al.COX-2/EGFRexpression and survival among women withadenocarcinoma of the lung[J].Carcinogenesis,2008,29(9):1781-1787.
• [5]Muir VJ,Dhillon S.Erlotinib:as maintenancemonotherapy in non-small cell lung cancer[J].BioDrugs,2011,25(3):139-146.
• [6]Krause DS,Van Etten RA.Tyrosine kinases as targets forcancer therapy[J].N Engl J Med,2005,353(2):172-187.
• [7]Zhang Z,Stiegler AL,Boggon TJ,et al.EGFR-mutatedlung cancer:a paradigm of molecular oncology[J].Oncotarget,2010,1(7):497-514.
• [8]Fukuoka M,Yano S,Giaccone G,et al.Multi-institutionalrandomized phaseⅡtrial of gefitinib for previously treatedpatients with advanced non-small cell lung cancer[J].JClin Oncol,2003,21(12):2237-2246.
• [9]Shepherd FA,Rodrigues Pereira J,Ciuleanu T,et al.Erlotinib in previously treated non-small cell lung cancer[J].N Engl JMed,2005,353(2):123-132.
• [10]Lynch TJ,Bell DW,Sordella R,et al.Activatingmutations in the epidermal growth factor receptorunderlying responsiveness of non-small cell lung cancerto gefitinib[J].N Engl J Med,2004,350(21):2129-2139.
• [11]Ishikawa N,Daigo Y,Takano A,et al.Increases ofamphiregulin and transforming growth factor-a in serumas predictors of poor response to gefitinib among patientswith advanced non-small cell lung cancers[J].CancerRes,2005,65(20):9176-9184.
• [12]Shigematsu H,Gazdar AF.Somatic mutations ofepidermal growth factor receptor signaling pathway inlung cancers[J].Int J Cancer,2006,118(2):257-262.
• [13]Goto K,Ichinose Y,Ohe Y,et al.Epidermal growthfactor receptor mutation status in circulating free DNA inserum:From IPASS,a phaseⅢstudy of gefitinib orcarboplatin/paclitaxel in non-small cell lung cancer[J].J Thorac Oncol,2012,7(1):115-121.
• [14]Sequist LV,Bell DW,Lynch TJ,et al.Molecularpredictors of response to epidermal growth factor receptorantagonists in non-small cell lung cancer[J].J ClinOncol,2007,25(5):587-595.
• [15]Hirsch FR,Varella-Garcia M,Bunn PA Jr,et al.Epidermal growth factor receptor in non-small cell lungcarcinomas:correlation between gene copy number andprotein expression and impact on prognosis[J].J ClinOncol,2003,21(20):3798-3807.
• [16]Hirsch FR,Varella-Garcia M,Cappuzzo F,et al.Combination of EGFR gene copy number and proteinexpression predicts outcome for advanced non-small celllung cancer patients treated with gefitinib[J].AnnOncol,2007,18(4):752-760.
• [17]Cappuzzo F,Hirsch FR,Rossi E,et al.Epidermal growthfactor receptor gene and protein and gefitinib sensitivityin non-small cell lung cancer[J].J Natl Cancer Inst,2005,97(9):643-655.
• [18]Han SW,Kim TY,Jeon YK,et al.Optimization of patientselection for gefitinib in non-small cell lung cancer bycombined analysis of epidermal growth factor receptormutation,K-ras mutation,and Akt phosphorylation[J].Clin Cancer Res,2006,12(8):2538-2544.
• [19]Wheeler DL,Dunn EF,Harari PM.Understandingresistance to EGFR inhibitors-impact on future treatmentstrategies[J].Nat Rev Clin Oncol,2010,7(9):493-507.
• [20]Perez-Soler R.HER1/EGFR targeting:refining thestrategy[J].Oncologist,2004,9(1):58-67.
• [21]Hirsch FR,Varella-Garcia M,Bunn PA Jr,et al.Molecular predictors of outcome with gefitinib in a phaseⅢplacebo-controlled study in advanced non-small celllung cancer[J].J Clin Oncol,2006,24(31):5034-5042.
• [22]Tsao MS,Sakurada A,Cutz JC,et al.Erlotinib in lungcancer-molecular and clinical predictors of outcome[J].N Engl J Med,2005,353(2):133-144.
• [23]Parra HS,Cavina R,Latteri F,et al.Analysis ofepidermal growth factor receptor expression as apredictive factor for response to gefitinib('Iressa',ZD1839)in non-small cell lung cancer[J].Br JCancer,2004,91(2):208-212.
• [24]Engelman JA,Zejnullahu K,Mitsudomi T,et al.METamplification leads to gefitinib resistance in lung cancerby activating ERBB3 signaling[J].Science,2007,316(5827):1039-1043.
• [25]Kobayashi S,Boggon TJ,Dayaram T,et al.EGFRmutation and resistance of non-small cell lung cancer togefitinib[J].N Engl J Med,2005,352(8):786-792.
• [26]Yun CH,Mengwasser KE,Toms AV,et al.The T790Mmutation in EGFR kinase causes drug resistance byincreasing the affinity for ATP[J].Proc Natl Acad SciUSA,2008,105(6):2070-2075.
• [27]Costa DB,Nguyen KS,Cho BC,et al.Effects of erlotinibin EGFR mutated non-small cell lung cancers withresistance to gefitinib[J].Clin Cancer Res,2008,14(21):7060-7067.
• [28]Wu SG,Chang YL,Hsu YC,et al.Good response togefitinib in lung adenocarcinoma of complex epidermalgrowth factor receptor(EGFR)mutations with theclassical mutation pattern[J].Oncologist,2008,13(12):1276-1284.
• [29]Maheswaran S,Sequist L,Nagrath S,et al.Detection ofmutation in EGFR in circulating lung cancer cells[J].N Engl J Med,2008,359(8):1-12.
• [30]Costa DB,Schumer ST,Tenen DG,et al.Differentialresponses to erlotinib in epidermal growth factor receptor(EGFR)-mutated lung cancers with acquired resistanceto gefitinib carrying the L747S or T790M secondarymutations[J].J Clin Oncol,2008,26(7):1182-1186.
• [31]Balak MN,Gong Y,Riely GJ,et al.Novel D761Y andcommon secondary T790M mutations in epidermal growthfactor receptor-mutant lung adenocarcinomas withacquired resistance to kinase inhibitors[J].Clin CancerRes,2006,12(21):6494-6501.
• [32]Bean J,Riely GJ,Balak M,et al.Acquired resistance toepidermal growth factor receptor kinase inhibitorsassociated with a novel T854A mutation in a patient withEGFR-mutant lung adenocarcinoma[J].Clin CancerRes,2008,14(22):7519-7525.
• [33]Der CJ,Krontiris TG,Cooper GM.Transforming genes ofhuman bladder and lung carcinoma cell lines arehomologous to the ras genes of Harvey and Kirstensarcoma viruses[J].Proc Natl Acad Sci USA,1982,79(11):3637-3640.
• [34]Mansi L,Viel E,Curtit E,et al.Targeting the RASsignalling pathway in cancer[J].Bull Cancer,2011,98(9):1019-1028.
• [35]Tam IY,Chung LP,Suen WS,et al.Distinct epidermalgrowth factor receptor and KRASmutation patterns innon-small cell lung cancer patients with different tobaccoexposure and clinicopathologic features[J].Clin CancerRes,2006,12(5):1647-1653.
• [36]Friday BB,Adjei AA.KRAS as a target for cancertherapy[J].Biochem Biophysi Acta,2005,1756(2):127-144.
• [37]Pao W,Wang TY,Riely GJ,et al.KRAS mutations andprimary resistance of lung adenocarcinomas to gefitinibor erlotinib[J].PLoS Med,2005,2(1):e17.
• [38]Birchmeier C,Birchmeier W,Gherardi E,et al.Met,metastasis,motility and more[J].Nat Rev Mol CellBiol,2003,4(12):915-925.
• [39]Masuya D,Huang C,Liu D,et al.The tumour-stromalinteraction between intratumoral c-Met and stromalhepatocyte growth factor associated with tumour growthand prognosis in non-small cell lung cancer patients[J].Br J Cancer,2004,90(8):1555-1562.
• [40]Bonanno L,Jirillo A,Favaretto A.Mechanisms ofacquired resistance to epidermal growth factor receptortyrosine kinase inhibitors and new therapeuticperspectives in non small cell lung cancer[J].CurrDrug Targets,2011,12(6):922-933.
• [41]Matsubara D,Ishikawa S,Sachiko O,et al.Co-activationof epidermal growth factor receptor and c-MET defines adistinct subset of lung adenocarcinomas[J].Am JPathol,2010,177(5):2191-2204.
• [42]Yi HK,Kim SY,Hwang PH,et al.Impact of PTEN onthe expression of insulin-like growth factors(IGFs)andIGF-binding proteins in human gastric adenocarcinomacells[J].Biochem Biophys Res Commun,2005,330(3):760-767.
• [43]Simpson L,Parsons R.PTEN:life as a tumor suppressor[J].Exp Cell Res,2001,264(1):29-41.
• [44]Kokubo Y,Gemma A,Noro R,et al.Reduction of PTENprotein and loss of epidermal growth factor receptor genemutation in lung cancer with natural resistance togefitinib(IRESSA)[J].Br J Cancer,2005,92(9):1711-1719.
• [45]Lim WT,Zhang WH,Miller CR,et al.PTEN andphosphorylated AKT expression and prognosis in early-and late-stage non-small cell lung cancer[J].OncolRep,2007,17(4):853-857.
• [46]Tang JM,He QY,Guo RX,et al.Phosphorylated Aktoverexpression and loss of PTEN expression in non-smallcell lung cancer confers poor prognosis[J].LungCancer,2006,51(2):181-191.
• [47]Coolican SA,Samuel DS,Ewton DZ,et al.The mitogenicand myogenic actions of insulin-like growth factors utilizedistinct signaling pathways[J].J Biol Chem,1997,272(10):6653-6662.
• [48]Cappuzzo F,Toschi L,Tallini G,et al.Insulin-likegrowth factor receptor 1(IGFR-1)is significantlyassociated with longer survival in non-small cell lungcancer patients treated with gefitinib[J].Ann Oncol,2006,17(7):1120-1127.
• [49]Xu Y,Liu H,Chen J,et al.Acquired resistance of lungadenocarcinoma to EGFR-tyrosine kinase inhibitorsgefitinib and erlotinib[J].Cancer Biol Ther,2010,9(8):572-582.
• [50]Chakravarti A,Loeffler JS,Dyson NJ.Insulin-like growthfactor receptor I mediates resistance to anti-epidermalgrowth factor receptor therapy in primary humanglioblastoma cells through continued activation ofphosphoinositide 3-kinase signaling[J].Cancer Res,2002,62(1):200-207.
• [51]Frederick BA,Helfrich BA,Coldren CD,et al.Epithelialto mesenchymal transition predicts gefitinib resistance incell lines of head and neck squamous cell carcinoma andnon-small cell lung carcinoma[J].Mol Cancer Ther,2007,6(6):1683-1691.
• [52]Uramoto H,Iwata T,Onitsuka T,et al.Epithelial-mesenchymal transition in EGFR-TKI acquired resistantlung adenocarcinoma[J].Anticancer Res,2010,30(7):2513-2517.
• [53]Thomson S,Buck E,Petti F,et al.Epithelial tomesenchymal transition is a determinant of sensitivity ofnon-small cell lung carcinoma cell lines and xenograftsto epidermal growth factor receptor inhibition[J].Cancer Res,2005,65(20):9455-9462.
• [54]Wen J,Fu J,Zhang W,et al.Genetic and epigeneticchanges in lung carcinoma and their clinical implications[J].Mod Pathol,2011,24(7):932-943.